Observational studyFrontiers in endocrinology2025
Gestational diabetes increases preterm membrane rupture risk through elevated hydroxydesmethylpiperine sulfate levels.
Observational study in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Phenotypes of Preterm Birth: A Retrospective Cohort Study from a Tertiary Romanian Centre as a Framework for Future Genomic and Proteomic Research.Journal of clinical medicine · 2026Article
- Prevalence and risk factors of gestational diabetes mellitus in Nanning, Guangxi, China: a cross-sectional study.Frontiers in endocrinology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Gestational diabetes mellitus (GDM) is a metabolic disorder that increases the risk of premature rupture of membranes (PROM). The link between GDM-associated metabolic dysregulation and PROM remains unclear. This study investigates the underlying metabolic mechanisms to identify potential therapeutic targets for improving pregnancy outcomes. Methods: The study involved 354 mothers from the GDM Mother and Child Study (GMCS) at Wuxi People's Hospital, Nanjing Medical University. A regression model assessed the GDM-PROM relationship. Third-trimester serum metabolites were analyzed using ultra-high-performance liquid chromatography and high-resolution mass spectrometry. Results: A higher percentage of women with PROM were diagnosed with GDM (15.7% vs. 32.3%, P=0.005). Although no significant differences were found in 1-h and 2-h glucose levels (P=0.216 and 0.129), fasting glucose was elevated in the PROM group (4.50 [0.43] vs. 4.73 [0.71], P=0.017). Both unadjusted and adjusted models confirmed GDM as a risk factor for PROM (OR: 2.548, 95% CI: 1.341-4.759; P=0.004). After adjusting for confounders, GDM remained positively associated with PROM risk (OR: 2.538, 95% CI: 1.223-5.224; P=0.012). Hydroxydesmethylpiperine sulfate levels were significantly elevated in all study groups. Conclusion: GDM elevates PROM risk by disrupting fetal membrane integrity through metabolic alterations. Elevated hydroxydesmethylpiperine sulfate levels in GDM-PROM cases indicate its potential as a PROM risk biomarker, underscoring the importance of early metabolic screening and glycemic control. Further research should explore this metabolite's mechanisms and therapeutic potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.